A Randomised, Double-Blind, Parallel Group, Multicentre Study to Assess the Efficacy and Safety of Four Concentrations of Depigoid Phleum versus Placebo in Patients with Allergic Rhinitis and/or Rhinoconjunctivitis with or without Intermittent Asthma

Trial Profile

A Randomised, Double-Blind, Parallel Group, Multicentre Study to Assess the Efficacy and Safety of Four Concentrations of Depigoid Phleum versus Placebo in Patients with Allergic Rhinitis and/or Rhinoconjunctivitis with or without Intermittent Asthma

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Aug 2016

At a glance

  • Drugs Grass pollen allergy immunotherapy (Primary)
  • Indications Allergic conjunctivitis; Allergic rhinitis
  • Focus Therapeutic Use
  • Sponsors LETI Pharma GmbH
  • Most Recent Events

    • 20 Aug 2016 Status changed from recruiting to completed.
    • 09 Aug 2016 The trial was completed in Germany ( end date:2016-05-13)
    • 21 May 2016 The trial was completed in Spain ( end date:2016-05-13)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top